SUPNSupernus Pharmaceuticals, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 22197
Ticker: SUPN
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2012-05-01
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: SUPN

Detail

Enriched 2026-08-14 20:47

Market cap: $2,784,502,207.87
Shares outstanding (class): 58,127,013
Shares outstanding (weighted): 58,168,001
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 778
Location: ROCKVILLE, MD
Homepage: https://www.supernus.com
Description: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Market cap and share counts drift.

Funds holding this security

185 funds · 188 positions · $840.50M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Core S&P Small-Cap ETF iShares Trust	IJR	$177.94M	0.19%	3,442,502 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$89.52M	0.00%	1,731,805 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$69.66M	0.10%	1,347,725 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$65.13M	0.04%	1,259,973 NS	FIGI
VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS	VBR	$41.43M	0.07%	801,453 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$33.10M	0.04%	640,334 NS	FIGI
State Street(R) SPDR(R) Portfolio S&P 600(TM) S… SPDR SERIES TRUST	SPSM	$26.81M	0.19%	518,575 NS	FIGI
Loomis Sayles Small Cap Growth Fund LOOMIS SAYLES FUNDS II	—	$24.61M	1.28%	476,016 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$22.41M	0.18%	433,579 NS	FIGI
VANGUARD TAX-MANAGED SMALL-CAP FUND VANGUARD TAX-MANAGED FUNDS	—	$19.41M	0.20%	375,471 NS	FIGI
iShares S&P Small-Cap 600 Growth ETF iShares Trust	IJT	$17.63M	0.27%	340,996 NS	FIGI
AMG GW&K Small Cap Core Fund AMG Funds	—	$11.74M	1.74%	227,137 NS	FIGI
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$11.21M	0.12%	216,873 NS	FIGI
State Street(R) SPDR(R) S & P 600(TM) Small Cap… SPDR SERIES TRUST	SLYG	$10.79M	0.27%	208,703 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$9.37M	0.23%	181,207 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERSUPN
FIGI_COMPOSITEBBG000BP0HX7
FIGI_SHARE_CLASSBBG001SFKFF1
CIK0001356576
ISINUS8684591089
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Supernus Pharmaceuticals is a biopharmaceutical company focused on CNS treatments, classified under pharmaceuticals.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.